February 2017
Vol 0 | Issue 0

Q&A with Family Office & Life Science Symposium

Small Cap Nation

Principle Series:

Join Small Cap Nation as we host our Family Office & Life Science Symposium at the NASDAQ MarketSite taking place on February 21, 2017.


Family Office Insights is a voluntary, “opt-in” collaborative peer-to-peer community of single family offices, qualified investors and institutional investors. Join the community here www.familyofficeinsights.com



Family Office & Life Science Symposium

Join Small Cap Nation as we host our Family Office & Life Science Symposium at the NASDAQ MarketSite taking place on February 21, 2017. You can register here.

The Family Office Investment Symposium is an ongoing series that identifies superior transition-stage private and public biotech, life science, healthcare and medical technology companies. These highlighted companies are focused on the latest disruptive technologies and relevant industry trends. The SCN symposiums are designed to connect a curated group of highly vetted companies with a purposely selected group of sophisticated investors. Small Cap Nation has designed this invite-only event to generate unparalleled discovery opportunities and exclusive networking sessions. All registrants will receive a confirmation email along with event details.

Agenda:

1:30PM Registration

2:00 PM Welcome from Small Cap Nation SymposiumIntroduction by: Hugh Austin, CEO, Small Cap Nation. Jane King: Host & Moderator

2:10-2:40PM Developing a Framework for Deploying Capital into Healthcare: Strategies to De-risk Investments While Creating Impact: A discussion providing strategies and disciplines to guide deployment of capital into various healthcare sub-sectors.

  • Public companies – special situations, valuations
  • Provided checklist of success criteria: quality of leadership/management, commercialization experience, corporate governance, addressable market, KOL support/SAB, rare/orphan indications, disruptive technology/therapy, global implications, milestones, execution

Andrew Schneider, Family Office Networks

Tom McKenzie, Cavendish Global

Arthur Andrew Bavelas, Family Office Insights

Steven Christmann, Christmann-Guttermann Family Office

2:40 – 3:10PM How to Differentiate Investment in Private & Public Companies in Large Disease States & Exploring the SubSectors: A moderated discussion introducing the latest innovation and technologies pursuing large disease states, within the context of committing capital to a private company versus a public company.

  • How to differentiate investment in private & public companies
  • Differentiated approaches to investing in cancer (public vs. private)
  • Exploring the subsectors: considerations for why to invest in pharma, med tech and biotech

Jeff Geschwind, M.D., CEO Prescience Labs& Oncology KOL

Chiara Russo, Analyst, Cantor

Ramses Ertdmann, (Former EVP Corporate Affairs Pharmacyclics)

Joel S Ross, MD Founder Cogwellin

BREAK: 3:10– 3:20

3:20 – 4:20 PM The Public Opportunities

Acel RX (NASDAQ: ACRX) – Tim Morris, CFO

Amyris (NASDAQ: AMRS) – John Melo, CEO

Cellular Biomedicine Group (NASDAQ: CBMG) – Tony Liu, CEO

Dicerna (NASDAQ: DRNA) – Doug Fambrough, Ph.D., CEO & President

Hemispherics (NYSE: HEB) – Thomas Equels, M.S., J.D., CEO & President

Sensus Healthcare (NASDDAQ: SRTS) – Joe Sardano, Chmn, CEO & President

4:20 – 5:00PM The Private Opportunities

AZ Therapeutics (PRIVATE) – David Elmaleh, Ph.D., CEO

Geneius Biotech (PRIVATE) – Alfred Slanetz, Chairman & CEO

Lung Therapeutics (PRIVATE) – Brian Windsor, Ph.D., CEO

Myomo (PRIVATE) – Paul Gudonis, CEO

Prescience Labs (PRIVATE) – Jeff Geschwind, CEO / Jason Rifkin, President

5:00 – 6:00 PM Networking Cocktail Reception & One-on-One